143 related articles for article (PubMed ID: 16453395)
21. The vexations of Vioxx.
Sibbald B
CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046
[No Abstract] [Full Text] [Related]
22. Tough-talking journal editor faces accusations of leniency.
McNeil DG
N Y Times Web; 2006 Aug; ():F1, F3. PubMed ID: 16906685
[No Abstract] [Full Text] [Related]
23. Panel faults Pfizer in '96 clinical trial in Nigeria.
Stephens J
Washington Post; 2006 May; ():A1, A21. PubMed ID: 16718960
[No Abstract] [Full Text] [Related]
24. Bringing the FDA's Information to Market.
Woloshin S; Schwartz LM
Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960
[No Abstract] [Full Text] [Related]
25. Full disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors.
Rifai N; Plebani M; Wu A; Brugnara C; Delvin E; Lamb EJ; Ness PM; Wick MR; Berg JP
Transfusion; 2012 Jun; 52(6):e15-6. PubMed ID: 22686537
[No Abstract] [Full Text] [Related]
26. Bias in the design, interpretation, and publication of industry-sponsored clinical research.
Hammerschmidt D
Minn Med; 2008 Jun; 91(6):46-7. PubMed ID: 18616022
[No Abstract] [Full Text] [Related]
27. Journal grows suspicious of Vioxx data.
Wadman M
Nature; 2005 Dec; 438(7070):899. PubMed ID: 16355178
[No Abstract] [Full Text] [Related]
28. Lessons learned after the withdrawal of rofecoxib.
Giaquinta D
Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801
[No Abstract] [Full Text] [Related]
29. Merck cleared in personal injury case against Vioxx.
Mayor S
BMJ; 2005 Nov; 331(7525):1101. PubMed ID: 16282390
[No Abstract] [Full Text] [Related]
30. Learning the value of drugs--is rofecoxib a regulatory success story?
Eisenberg RS
N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
[No Abstract] [Full Text] [Related]
31. How to avoid another 'Vioxx'.
Frantz S
Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
[No Abstract] [Full Text] [Related]
32. Full-disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors.
Rifai N; Plebani M; Wu AH; Delanghe J; Brugnara C; Delvin E; Lamb EJ; Ness PM; Wick MR; Berg JP
Clin Chim Acta; 2011 Mar; 412(7-8):491-2. PubMed ID: 21159312
[No Abstract] [Full Text] [Related]
33. Blood, sweat and tears.
Magnus D
Am J Bioeth; 2006; 6(3):1-2. PubMed ID: 16754438
[No Abstract] [Full Text] [Related]
34. Conflicts of interest: part 1: Reconnecting the dots--reinterpreting industry-physician relations.
Rosenbaum L
N Engl J Med; 2015 May; 372(19):1860-4. PubMed ID: 25946288
[No Abstract] [Full Text] [Related]
35. COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
Fendrick AM
Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263
[No Abstract] [Full Text] [Related]
36. The impact of selective publication on clinical research in pain.
Rowbotham MC
Pain; 2008 Dec; 140(3):401-404. PubMed ID: 19004556
[No Abstract] [Full Text] [Related]
37. Implications of the rofecoxib trials.
Kozma CM
Manag Care Interface; 2005 Oct; 18(10):61-2. PubMed ID: 16265937
[No Abstract] [Full Text] [Related]
38. The sad story of Vioxx, and what we should learn from it.
Karha J; Topol EJ
Cleve Clin J Med; 2004 Dec; 71(12):933-4, 936, 938-9. PubMed ID: 15641522
[No Abstract] [Full Text] [Related]
39. Merck's actions surrounding Vioxx.
Heinley M
PLoS Med; 2006 Jun; 3(6):e286; author reply e285. PubMed ID: 16789808
[No Abstract] [Full Text] [Related]
40. Evaluating drug effects in the post-Vioxx world: there must be a better way.
Avorn J
Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
